Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat diet-induced obese mice
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have favorable cardiovascular outcomes in patients with diabetes. However, whether SGLT2i can improve obesity-related cardiac dysfunction is unknown. Sestrin2 is a novel stress-inducible protein that regulates AMPK–mammalian target of rapamycin (mTOR) and suppresses oxidative damage. The aim of this study was to determine whether empagliflozin (EMPA) improves obesity-related cardiac dysfunction via regulating Sestrin2-mediated pathways in diet-induced obesity. C57BL/6J mice and Sestrin2 knockout mice were fed a high-fat diet (HFD) for 12 weeks and then treated with or without EMPA (10 mg/kg) for 8 weeks. Treating HFD-fed C57BL/6J mice with EMPA reduced body weight and whole-body fat and improved metabolic disorders. Furthermore, EMPA improved myocardial hypertrophy/fibrosis and cardiac function and reduced cardiac fat accumulation and mitochondrial injury. Additionally, EMPA significantly augmented Sestrin2 levels and increased AMPK and endothelial nitric oxide synthase phosphorylation, but inhibited Akt and mTOR phosphorylation. These beneficial effects were partially attenuated in HFD-fed Sestrin2 knockout mice. Intriguingly, EMPA treatment enhanced the Nrf2/HO-1–mediated oxidative stress response, suggesting antioxidant and anti-inflammatory activity. Thus, EMPA improved obesity-related cardiac dysfunction via regulating Sestrin2-mediated AMPK-mTOR signaling and maintaining redox homeostasis. These findings provide a novel mechanism for the cardiovascular protection of SGLT2i in obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, several antifibrotic interventions -including traditional Chinese medicinal (TCM) compounds and pharmaceutical agents such as metformin, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is)- promote restorative macrophage polarization, at least in part, through activation of AMPK-dependent pathways and enhance hepatic autophagy (34, 39, 41–44).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [43]
Citations
Cites
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 2×
“Sesn2 also promotes phosphorylation of AMPK through its upstream kinase liver kinase B1 (LKB1)– dependent way and mediates genotoxic stress-induced AMPK activation and mTOR inhibition (12,13).”
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Self-citationZhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · cited 1×
“We found that EMPA treatment triggered eNOS phosphorylation at Ser(1177), indicating endothelial-protective effects of EMPA, which is consistent with a previous study (42).”
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Bae, S. H., Sung, S. H., Oh, S. Y., Lim, J. M., Lee, S. K., Park, Y. N., Lee, H. E., Kang, D., & Rhee, S. G. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2012.12.002 · Cited by 492 · cited 1×
“(41) reported that Sesn2 induces Nrf2 activation by enhancing the autophagic degradation of Keap1.”
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368
Fitchett, D., Inzucchi, S. E., Cannon, C. P., McGuire, D. K., Scirica, B. M., Johansen, O. E., Sambevski, S., Kaspers, S., Pfarr, E., George, J. T., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037778 · Cited by 351
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 348
Yurista, S. R., Silljé, H. H. W., Oberdorf-Maass, S. U., Schouten, E.-M., Pavez Giani, M. G., Hillebrands, J.-L., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1473 · Cited by 321
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1548 · Cited by 222
Buss, S. J., Muenz, S., Riffel, J. H., Malekar, P., Hagenmueller, M., Weiss, C. S., Bea, F., Bekeredjian, R., Schinke-Braun, M., Izumo, S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.031 · Cited by 213
Kuwabara, Y., Horie, T., Baba, O., Watanabe, S., Nishiga, M., Usami, S., Izuhara, M., Nakao, T., Nishino, T., Otsu, K., et al. (2015) · Circulation Research · doi:10.1161/circresaha.116.304707 · Cited by 212
Differential Role of Leptin and Adiponectin in Cardiovascular System
Ghantous, C. M., Azrak, Z., Hanache, S., Abou-Kheir, W., & Zeidan, A. (2015) · International Journal of Endocrinology · doi:10.1155/2015/534320 · Cited by 204
Obesity and cardiovascular disease: From pathophysiology to risk stratification
Marinou, K., Tousoulis, D., Antonopoulos, A. S., Stefanadi, E., & Stefanadis, C. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.03.135 · Cited by 190
Yang, J. H., Obokata, M., Reddy, Y. N. V., Redfield, M. M., Lerman, A., & Borlaug, B. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1671 · Cited by 178
The microcirculation: a key player in obesity-associated cardiovascular disease
Sorop, O., Olver, T. D., van de Wouw, J., Heinonen, I., van Duin, R. W., Duncker, D. J., & Merkus, D. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx093 · Cited by 177
Di Franco, A., Cantini, G., Tani, A., Coppini, R., Zecchi-Orlandini, S., Raimondi, L., Luconi, M., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.032 · Cited by 163
Sestrin2 promotes LKB1‐mediated AMPK activation in the ischemic heart
Morrison, A., Chen, L., Wang, J., Zhang, M., Yang, H., Ma, Y., Budanov, A., Lee, J. H., Karin, M., & Li, J. (2015) · The FASEB Journal · doi:10.1096/fj.14-258814 · Cited by 157
Self-citationJanus-faced Sestrin2 controls ROS and mTOR signalling through two separate functional domains
Kim, H., An, S., Ro, S.-H., Teixeira, F., Jin Park, G., Kim, C., Cho, C.-S., Kim, J.-S., Jakob, U., Hee Lee, J., et al. (2015) · Nature Communications · doi:10.1038/ncomms10025 · Cited by 154
AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1
Li, Y., Chen, C., Yao, F. J., Su, Q., Liu, D., Xue, R., Dai, G., Fang, R., Zeng, J., Chen, Y., et al. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.023 · Cited by 144
Akt1 in the cardiovascular system: friend or foe?
O'Neill, B. T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25900 · Cited by 140
AMPK: a therapeutic target of heart failure—not only metabolism regulation
Li, X., Liu, J., Lü, Q., Ren, D., Sun, X., Rousselle, T. V., Tan, Y., & Li, J. (2018) · Bioscience Reports · doi:10.1042/bsr20181767 · Cited by 128
Self-citationQuan, N., Sun, W., Wang, L., Chen, X., Bogan, J. S., Zhou, X., Cates, C., Liu, Q., Zheng, Y., & Li, J. (2017) · The FASEB Journal · doi:10.1096/fj.201700063r · Cited by 123
Self-citationOvernutrition, mTOR signaling, and cardiovascular diseases
Jia, G., Aroor, A. R., Martinez-Lemus, L. A., & Sowers, J. R. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00262.2014 · Cited by 122 · cited 1×
“In obesity, activated mTOR can phosphorylate p70 S6 kinase, which is involved in myocardial proliferation and hypertrophy (36,37).”
Wang, L., Quan, N., Sun, W., Chen, X., Cates, C., Rousselle, T., Zhou, X., Zhao, X., & Li, J. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy033 · Cited by 121
Self-citationErkens, R., Kramer, C. M., Lückstädt, W., Panknin, C., Krause, L., Weidenbach, M., Dirzka, J., Krenz, T., Mergia, E., Suvorava, T., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.10.409 · Cited by 108
Wu, P., Wen, W., Li, J., Xu, J., Zhao, M., Chen, H., & Sun, J. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0958-2441 · Cited by 107
Self-citationEmpagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
Lü, Q., Liu, J., Li, X., Sun, X., Zhang, J., Ren, D., Tong, N., & Li, J. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110642 · Cited by 107
Self-citationPromise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond
Martens, P., Mathieu, C., & Verbrugge, F. H. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0522-x · Cited by 99
Kim, H. J., Joe, Y., Kim, S.-K., Park, S.-U., Park, J., Chen, Y., Kim, J., Ryu, J., Cho, G. J., Surh, Y.-J., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.05.026 · Cited by 96
Sestrin2 prevents age-related intolerance to post myocardial infarction via AMPK/PGC-1α pathway
Quan, N., Wang, L., Chen, X., Luckett, C., Cates, C. A., Rousselle, T. V., Zheng, Y., & Li, J. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.005 · Cited by 96
Self-citationChronic high fat diet induces cardiac hypertrophy and fibrosis in mice
Wang, Z., Li, L., Zhao, H., Peng, S., & Zuo, Z. (2015) · Metabolism · doi:10.1016/j.metabol.2015.04.010 · Cited by 93
Chan, A. Y. M., & Dyck, J. R. B. (2005) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-107 · Cited by 74
Yen, J.-H., Huang, S., Huang, H.-S., Fong, Y., Wu, Y., Chiang, J., & Su, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1016-9 · Cited by 64
Obesity and Cardiometabolic Defects in Heart Failure Pathology
Halade, G. V., & Kain, V. (2017) · Comprehensive physiology · doi:10.1002/cphy.c170011 · Cited by 52
Li, X., Liu, J., Hu, H., Lu, S., Lü, Q., Quan, N., Rousselle, T. V., Patel, M. S., & Li, J. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy272 · Cited by 45
Self-citationSodium‐Glucose Linked Transporter‐2 Inhibitors in Chronic Kidney Disease
Zanoli, L., Granata, A. R. M., Lentini, P. L. M., Rastelli, S., Fatuzzo, P. M., Rapisarda, F., & Castellino, P. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/317507 · Cited by 43
High free fatty acids level related with cardiac dysfunction in obese rats
Sun, X., Pan, H., Tan, H., & Yu, Y. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.028 · Cited by 41
Self-citationDong, B., Xue, R., Sun, Y., Dong, Y., & Liu, C. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3020-2 · Cited by 36
L-Carnitine Attenuates Cardiac Dysfunction by Ischemic Insults Through Akt Signaling Pathway
Xue, M., Chen, X., Guo, Z., Liu, X., Bi, Y., Yin, J., Hu, H., Zhu, P., Zhuang, J., Cates, C. A., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx193 · Cited by 23
Self-citationA20 prevents obesity-induced development of cardiac dysfunction
Xu, W., Wang, C., Liang, M., Chen, L., Fu, Q., Zhang, F., Wang, Y., Huang, D., & Huang, K. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1608-3 · Cited by 23
Myocardial redox status, mitophagy and cardioprotection: a potential way to amend diabetic heart?
Bai, T., Wang, F., Zheng, Y., Liang, Q., Wang, Y., Kong, J., & Cai, L. (2016) · Clinical Science · doi:10.1042/cs20160168 · Cited by 16
Kondo, H., & Takahashi, N. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz073 · Cited by 13
Cited by
Bhatti, J. S., Sehrawat, A., Mishra, J., Sidhu, I. S., Navik, U., Khullar, N., Kumar, S., Bhatti, G. K., & Reddy, P. H. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.019 · Cited by 693
Ketone bodies: from enemy to friend and guardian angel
Kolb, H., Kempf, K., Röhling, M., Lenzen-Schulte, M., Schloot, N. C., & Martin, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-02185-0 · Cited by 361
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“Reduced mTOR Signaling n/a Yes [51] Yes [51] Yes [52] Yes [53]”
BackgroundAn Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 256
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Metadata
- Authors
- Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J.
- Affiliations
- Weifang Medical University (CN)
- Department of Physiology and Biophysics, Mississippi Center for Heart Research, University of Mississippi Medical Center, Jackson, MS
- University of Mississippi Medical Center (US)
- University of South Florida (US)
- University of California, Davis (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-03-31
- Volume
- 69
- Issue
- 6
- Pages
- 1292-1305
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3014209855
- Cited by
- 193
- References
- 46
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 39 · 2023: 36 · 2022: 43 · 2021: 29 · 2020: 7
- FWCI
- 17.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association (1-17-IBS-296)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- empagliflozin, SGLT2 inhibitors, obesity, cardiac dysfunction, Sestrin2, AMPK/mTOR signaling, redox homeostasis, oxidative stress, Nrf2/HO-1 pathway, endothelial nitric oxide synthase, cardiac hypertrophy, myocardial fibrosis, mitochondrial injury, high-fat diet, cardioprotection
- MeSH terms
- Sestrins, Adenylate Kinase, Animals, Benzhydryl Compounds, Dietary Fats, Gene Expression Regulation, Glucosides, Heart Diseases, Homeostasis, Obesity, Oxidation-Reduction, Peroxidases, Signal Transduction, Mice, TOR Serine-Threonine Kinases, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.